Not checkedNot checked for notices yet.
Role of trans-scleral diode cyclophotocoagulation in refractory glaucoma: A large retrospective study
Nimrita Nagdev, Vidya Raja, Kumar Saurabh and 1 more
TNOA Journal of Ophthalmic Science and Research · 2022
doi:10.4103/tjosr.tjosr_27_22 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Purpose: To study the efficacy and safety of Trans-scleral Cyclophotocoagulation (TS-CPC) to achieve adequate IOP reduction and a comfortable eye in refractory glaucoma. Material and Methods: The study was conducted at the glaucoma clinic of Aravind Eye Hospital, Madurai (TN). A total of 391 eyes of 317 patients treated from January 2019 – December 2019 with a minimum of 6 months and maximum follow-up up to 1 year were included in the study. Results: The Mean Pre-treatment IOP was 44.01 ± 14.06 mmHg. Mean post-treatment IOP at 1, 3, 6 months and up-to 1 year was 27.09 ± 14.07 mmHg, 22.65 ± 16.95 mmHg, 22.97 ± 16.60 and 22.88 ± 17.03mmHg, respectively. Complications encountered were pain and hypotony (1.7%). Conclusion: With the highest number of cases so far and with a longer follow-up period, we found that Trans-scleral Diode Cyclophotocoagulation is highly effective in lowering intraocular pressure. High success rate and low complication rate combined with portability, durability, and easy to learn technique make this procedure the treatment of choice for refractory and complex glaucoma.
Abstract licence: CC BY-NC-SA
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.